These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26297863)

  • 1. Advances in the treatment of cognitive impairment in Parkinson's disease.
    Goldman JG; Weintraub D
    Mov Disord; 2015 Sep; 30(11):1471-89. PubMed ID: 26297863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing Cognitive Impairment in Parkinson's Disease.
    Bailey M; Goldman JG
    Semin Neurol; 2017 Apr; 37(2):167-175. PubMed ID: 28511257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson's disease: a review.
    Leroi I; Collins D; Marsh L
    J Neurol Sci; 2006 Oct; 248(1-2):104-14. PubMed ID: 16806271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CERAD test performance and cognitive impairment in Parkinson's disease.
    Karrasch M; Laatu S; Martikainen K; Marttila R
    Acta Neurol Scand; 2013 Dec; 128(6):409-13. PubMed ID: 23668316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current management of the cognitive dysfunction in Parkinson's disease: how far have we come?
    Vale S
    Exp Biol Med (Maywood); 2008 Aug; 233(8):941-51. PubMed ID: 18535172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment.
    Goldman JG; Holden SK; Litvan I; McKeith I; Stebbins GT; Taylor JP
    Mov Disord; 2018 Apr; 33(4):503-510. PubMed ID: 29488270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonpharmacological enhancement of cognitive function in Parkinson's disease: a systematic review.
    Hindle JV; Petrelli A; Clare L; Kalbe E
    Mov Disord; 2013 Jul; 28(8):1034-49. PubMed ID: 23426759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis.
    Goetz CG; Emre M; Dubois B
    Ann Neurol; 2008 Dec; 64 Suppl 2():S81-92. PubMed ID: 19127578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurobiology of cognitive impairment in Parkinson's disease.
    Jellinger KA
    Expert Rev Neurother; 2012 Dec; 12(12):1451-66. PubMed ID: 23237352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cognitive Training in Parkinson's Disease - A New Therapy Option?].
    Kalbe E; Folkerts AK
    Fortschr Neurol Psychiatr; 2016 Jul; 84 Suppl 1():S24-35. PubMed ID: 27192506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of motor and cognitive impairment upon visually-guided saccades in Parkinson's disease.
    Macaskill MR; Graham CF; Pitcher TL; Myall DJ; Livingston L; van Stockum S; Dalrymple-Alford JC; Anderson TJ
    Neuropsychologia; 2012 Dec; 50(14):3338-47. PubMed ID: 23000134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New pharmacological options for treating advanced Parkinson's disease.
    Devos D; Moreau C; Dujardin K; Cabantchik I; Defebvre L; Bordet R
    Clin Ther; 2013 Oct; 35(10):1640-52. PubMed ID: 24011636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining mild cognitive impairment in Parkinson's disease.
    Caviness JN; Driver-Dunckley E; Connor DJ; Sabbagh MN; Hentz JG; Noble B; Evidente VG; Shill HA; Adler CH
    Mov Disord; 2007 Jul; 22(9):1272-7. PubMed ID: 17415797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The treatment of cognitive impairment associated with Parkinson's disease.
    Burn DJ
    Brain Pathol; 2010 May; 20(3):672-8. PubMed ID: 20522093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers of cognitive decline in Parkinson's disease.
    Lin CH; Wu RM
    Parkinsonism Relat Disord; 2015 May; 21(5):431-43. PubMed ID: 25737398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive impairment in Parkinson's disease.
    Cosgrove J; Alty JE; Jamieson S
    Postgrad Med J; 2015 Apr; 91(1074):212-20. PubMed ID: 25814509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A registry-based, case-control investigation of Parkinson's disease with and without cognitive impairment.
    Papapetropoulos S; Ellul J; Polychronopoulos P; Chroni E
    Eur J Neurol; 2004 May; 11(5):347-51. PubMed ID: 15142230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivastigmine in Parkinson's disease dementia.
    Chitnis S; Rao J
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):941-55. PubMed ID: 19619073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment.
    Svenningsson P; Westman E; Ballard C; Aarsland D
    Lancet Neurol; 2012 Aug; 11(8):697-707. PubMed ID: 22814541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal assessment of the pattern of cognitive decline in non-demented patients with advanced Parkinson's disease.
    Gasca-Salas C; Estanga A; Clavero P; Aguilar-Palacio I; González-Redondo R; Obeso JA; Rodríguez-Oroz MC
    J Parkinsons Dis; 2014; 4(4):677-86. PubMed ID: 25208730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.